Concerns Mount Over Trump's Impact on US Healthcare and Drug Prices
The article argues that high drug prices in the US are primarily due to pharmaceutical companies charging what the market can bear, not foreign countries paying less, and criticizes Trump's approach of blaming international partners instead of addressing systemic issues within the US pharmaceutical industry and global trade policies that favor profits over access to medicines.